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The 2003 International Society of Nephrology/Renal
Pathology Society (ISN/RPS) system for classifying patients
with lupus nephritis was based on glomerular lesions
exclusively, despite the fact that lupus nephritis affects all
compartments of the kidney. Hence, we analyzed the
tubulointerstitial lesions in patients with lupus nephritis
within the different classes and subclasses of the 2003 ISN/
RPS system. Among 313 patients from five centers in
northern China with lupus nephritis, interstitial inflammatory
cell infiltration, tubular atrophy, and interstitial fibrosis were
severe in 170 patients with class IV, moderate in 55 with class
III, and mild in 19 with class II and in 69 with class V disease,
each with significance. The severity of tubulointerstitial
lesions in classes IV-segmental and III was similar, whereas
the score of interstitial inflammatory cell infiltration in
patients with subclass IV-global was significantly higher than
that in those with subclass IV-segmental. Interstitial fibrosis
and tubular atrophy were each significantly more prominent
in patients with both active and chronic lesions than in those
with active lesions alone. The correlation coefficient ranged
from 0.222 to 0.811 comparing glomerular and
tubulointerstitial indices. In multivariate Cox hazard analysis
of tubulointerstitial lesions, indices of interstitial infiltration,
tubular atrophy, and interstitial fibrosis were confirmed as
significant independent risk factors for renal outcome. Thus,
we found that the 2003 ISN/RPS classification system of lupus
nephritis, based on glomerular lesions, could also reflect
related tubulointerstitial lesions. Hence, we suggest that the
extent of tubulointerstitial lesions may be helpful in
predicting renal outcome in patients with lupus nephritis.
Kidney International (2010) 77, 820–829; doi:10.1038/ki.2010.13;
published online 24 February 2010
KEYWORDS: classification; lupus nephritis; tubulointerstitial lesions
Lupus nephritis is common in patients with systemic lupus
erythematosus (SLE). The clinical and pathological manifesta-
tions are diverse and are associated with different therapeutic
response and prognosis in patients with lupus nephritis.1–2
A precise description of renal histopathological lesions and an
appropriate classification of lupus nephritis are both essential
for nephrologists to guide treatment and predict prognosis in
patients. Many distinguished rheumatologists, nephrologists,
and pathologists have dedicated themselves to improving and
refining the pathological classifications of lupus nephritis over
the past four decades. Since the first classification of lupus
nephritis issued by the WHO (World Health Organization) in
1974, it had been revised three times in 1982, 1995, and 2003,
respectively.3–6 The 2003 International Society of Nephrology
and Renal Pathology Society (ISN/RPS) classification has been
widely used internationally till now. This new classification was
based on glomerular lesions exclusively, despite the fact that
lupus nephritis could involve all renal components, including
the glomeruli, tubules, interstitium, and blood vessels. It is a
well-known fact that tubulointerstitial lesions are independent
risk factors in the progression of some glomerular diseases,
such as immunoglobulin (Ig)A nephropathy. Whether the
new classification of lupus nephritis, based on glomerular
lesions, could also reflect tubulointerstitial lesions has not
yet been investigated.
The current study evaluated the tubulointerstitial lesions
of 313 patients with lupus nephritis from five renal centers in
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North China, and comparisons were made among patients
with different classes and subclasses on the basis of the 2003
ISN/RPS classification.
RESULTS
Baseline data of patients with lupus nephritis
Patient profiles in this study are listed in Table 1a and b. The
age of onset of the 313 patients with lupus nephritis ranged
from 13 to 71 years, and the average age was 31.0 years. The
male-to-female ratio was 1:5.4.
According to the 2003 classification of lupus nephritis, 19
patients were classified as class II (6.1%), 55 cases as class III
(17.6%, including 18 cases of class Vþ III), 170 cases as class
IV (54.3%, 20 cases of class IV-segmental (IV-S) group and
150 cases of class IV-global (IV-G) group, including 22 cases
of class Vþ IV), and 69 cases as class V (22.0%). There were
no cases of classes I and VI in this study. Classes III and IV
were further subdivided into the active (A) group, the active/
chronic (A/C) group, and the chronic (C) group. Within class
III, the number of III(A) was 26, III(A/C) was 29, and III(C)
was 0. Within class IV-S, the number of IV-S (A) was 16, IV-S
(A/C) was 4, and IV-S (C) was 0. Within class IV-G, the
number of IV-G (A) was 107, IV-G (A/C) was 43, and IV-G
(C) was 0.
All patients received oral prednisone therapy. The majority
of patients completed treatment with oral cyclophosphamide
(62/313) or monthly intravenous cyclophosphamide (600–
800 mg per month) (166/313). The other patients received
mycophenolate mofetil (21/313), leflunomide (35/313), and
azathioprine (16/313). A total of 13 patients received
prednisone alone. Most of patients achieved clinical remis-
sion, 196 with complete remission and 96 with partial
remission. Overall, 21 patients presented with treatment
failure.
During follow-up of 61.5±34.9 months, three patients
died due to severe infection (2/313) or cerebral hemorrhage
(1/313). With regard to long-term renal outcome, 37 patients
reached the secondary end point including 6 with doubling
of serum creatinine and 31 with end-stage renal disease.
Comparison of tubulointerstitial lesions in different classes
of lupus nephritis
The scores of interstitial inflammatory cell infiltration,
tubular atrophy, and interstitial fibrosis among the four
classes were significantly different (Po0.001, Po0.001,
Po0.001, respectively). They were found to be the most
severe in class IV, moderate in class III, and mild in classes II
and V (details are provided in Figure 1a–c).
When we focused on the comparison between classes III
and IV, a further analysis of Mann–Whitney U-test showed
that the severity of interstitial inflammatory cell infiltration,
tubular atrophy, and interstitial fibrosis in class IV-S and class
III was similar (P¼ 0.669, P¼ 0.378, and P¼ 0.267, respec-
tively) and that the three indices were significantly higher in
the class IV-G group than in the class III group (Po0.001,
Po0.001, Po0.001, respectively). The score of interstitial
Table 1 | (a) General clinical profiles of patients at initial renal
biopsies; (b) renal pathological profiles of patients at initial
renal biopsies
(a)
Number of patients 313
Gender (male/female) 49/264
Age (mean±s.d.) (years) 31.0±7.6
The time between presentation of lupus nephritis
and biopsy (mean±s.d. and range) (months)
11.7±24.2 (0.5–96)
Number of hypertension
(blood pressureX140/90mmHg) (%)
160 (51.1)
Systolic blood pressure (mean and range)
(mmHg)
140 (105–175)
Diastolic blood pressure (mean and range)
(mmHg)
82 (75–92)
Number with fever (noninfectious) (%) 152 (48.6)
Number with malar rash (%) 176 (56.2)
Number with photosensitivity (%) 87 (27.8)
Number with oral ulcer (%) 101 (32.3)
Number with alopecia (%) 128 (40.9)
Number with arthralgia (%) 263 (84.0)
Number with serositis (%) 90 (28.8)
Number with neurological disorder (%) 21 (6.7)
Number with anemia (%) 196 (62.6)
Number with leukocytopenia(%) 154 (49.2)
Number with thrombocytopenia (%) 167 (53.4)
Number with hematuria (%) 223 (71.2)
Number with leukocyturia (noninfection) (%) 157 (50.2)
Number with acute renal failure (%) 78 (24.9)
Hemoglobin (mean±s.d.) (g/l) 101.5±24.2
Urine protein (mean±s.d.) (g per 24 h) 4.76±3.28
Serum creatinine (mean±s.d.) (mg/dl) 1.32±0.97
Number with positive ANA (%) 153 (100)
Number with positive anti-ds-DNA antibodies (%) 128 (40.9)
Number with positive anti-Sm antibodies (%) 91 (29.1)
Number with positive anti-SSA antibodies (%) 134 (42.8)
Number with positive anti-SSB antibodies (%) 37 (11.8)
Number with positive anti-RNP antibodies (%) 87 (27.8)
Number with anti-cardiolipin antibodies (%) 25/190(13.2)
C3 (mean±s.d.) (g/l) 0.37±0.14
SLEDAI (mean±s.d.) 18.9±6.8
Duration of follow-up (mean±s.d.) (months) 61.5±34.9
(b)
Number of biopsies 313
Number of glomeruli (mean±s.d.) 23.2±6.7
Activity indices (AIs) score (mean±s.d.) 8.49±3.98
Endocapillary hypercellularity (mean±s.d.) 2.58±1.12
Cellular crescents (mean±s.d.) 1.49±1.75
Karyorrhexis/fibrinoid necrosis (mean±s.d.) 1.12±0.77
Subendothelial hyaline deposits (mean±s.d.) 1.67±1.45
Interstitial inflammatory cell infiltration
(mean±s.d.)
1.92±0.83
Glomerular leukocyte infiltration (mean±s.d.) 0.78±0.43
Chronicity indices (CIs) score (mean±s.d.) 2.85±2.12
Glomerular sclerosis (mean±s.d.) 0.56±0.25
Fibrous crescents (mean±s.d.) 0.23±0.42
Tubular atrophy (mean±s.d.) 1.27±0.68
Interstitial fibrosis (mean±s.d.) 1.17±0.54
Vascular lesions 147/313 (47%)
Vascular deposits 76/147 (51.7%)
Thrombi 8/147 (5.4%)
Vasculitis 16/147 (10.9%)
Sclerosis 89/147 (60.5%)
Mild 21/147 (14.3%)
Moderate 112/147 (76.2%)
Severe 14/147 (9.5%)
Abbreviations: ANA, antinuclear antibody; RNP, ribonucleoprotein; SLEDAI, SLE Disease
Activity Index; SSA, Sjo¨gren’s syndrome A antigen; SSB, Sjo¨gren’s syndrome B antigen.
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inflammatory cell infiltration in patients with subclass IV-G
was significantly higher than that in those with subclass IV-S
(P¼ 0.008). There was no significant difference of tubular
atrophy and interstitial fibrosis between IV-G and IV-S
(P¼ 0.155 and P¼ 0.194, respectively) (details in Figure 2).
Comparison of tubulointerstitial lesions between patients
with active lesions (A group) and those with both active and
chronic lesions (A/C group) in class III and class IV
Scores of interstitial fibrosis and tubular atrophy in patients
in the A/C group were significantly higher than those in
patients in the A group (Po0.001 and Po0.001, respec-
tively). There was no significant difference of interstitial
inflammatory cell infiltration between the A/C and A groups
(P¼ 0.074) (details in Figure 3).
Correlation between scores of glomerular and
tubulointerstitial lesions
The score of interstitial inflammatory cell infiltration posi-
tively correlated with the scores of endocapillary hypercellu-
larity (r¼ 0.288), cellular crescents (r¼ 0.601), karyorrhexis/
fibrinoid necrosis (r¼ 0.609), subendothelial hyaline deposits
(r¼ 0.449), and glomerular leukocyte infiltration (r¼ 0.222).
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Figure 1 |Comparison of the tubulointerstitial lesions among
different classes of lupus nephritis. (a) Interstitial inflammation;
(b) tubular atrophy; (c) interstitial fibrosis.
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Figure 2 |Comparison of the tubulointerstitial lesions among
classes III, IV-S, and IV-G of lupus nephritis.
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Figure 3 |Comparison of the tubulointerstitial lesions
between patients with class III and class IV lupus nephritis
with active lesions (A group) and those with both active and
chronic lesions (A/C group).
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The score of tubular atrophy positively correlated with the
scores of glomerular sclerosis (r¼ 0.761) and fibrous
crescents (r¼ 0.811). The score of interstitial fibrosis also
positively correlated with the scores of glomerular sclerosis
(r¼ 0.391) and fibrous crescents (r¼ 0.298).
For further evaluating the correlations between glomerular
and tubulointerstitial injuries, the patients were further
divided into four groups according to the severity of
glomerular and tubulointerstitial lesions: group 1: nil or
mild glomerular lesions with nil or mild tubulointerstitial
lesions; group 2: moderate or severe glomerular lesions with
moderate or severe tubulointerstitial lesions; group 3: mode-
rate or severe glomerular lesions with nil or mild tubulo-
interstitial lesions; and group 4: nil or mild glomerular
lesions with moderate or severe tubulointerstitial lesions.
Clinical and laboratory characteristics were compared bet-
ween the four groups (details in Table 2). In group 1, patients
presented with the lowest ratio of acute renal failure (0%),
lowest amount of proteinuria (1.12±0.31 g per day), and the
best renal outcome (Po0.01, Po0.01, Po0.01, respectively).
In group 3, the time between presentation of lupus nephritis
and biopsy was the shortest (5.4±3.8 months, Po0.01). In
group 4, the ratio of anemia was the highest and the ratio of
hematuria was the lowest (Po0.01, Po0.01, respectively).
There did not exist any statistical difference in other indices
between the four groups.
Data of patients with lupus nephritis with repeat biopsies
Repeat kidney biopsy was carried out in 11 patients (Table 3).
Among them, seven were in relapse (No. 1–7) and four
underwent reevaluation after clinical remission (No. 8–11).
Most indices of tubulointerstitial lesions, especially inter-
stitial fibrosis and tubular atrophy, increased, although
patients achieved clinical remission.
Tubulointerstitial lesions as predictors for patients’ renal
survival
Using the log-rank test and Kaplan–Meier curves for
univariate survival analysis of renal prognosis of patients,
we especially focused on the indices of tubulointerstitial
lesions, including interstitial inflammatory cell infiltration,
interstitial fibrosis, and tubular atrophy, and found that they
were risk factors for renal outcome in lupus nephritis, that
is, the higher the score of the indices, the poorer the
Table 2 | Comparison of clinical characteristics between the four groups of patients with different severity of glomerular and
tubulointerstitial lesions
Group Total 1 2 3 4
Number of patients 313 12 145 141 15
Gender (male/female) 49/264 2/10 28/117 16/125 3/12
Age (mean±s.d.) (years) 31.0±7.6 25.0±5.3 33.0±8.1 28.0±4.3 32.0±1.7
The time between presentation of lupus nephritis
and biopsy (mean±s.d. and range) (months)
11.7±24.2 (0.5–96) 10.2±14.3 (0.5–48) 12.5±16.7 (2–96) 5.4±3.8 (0.5–12) 9.8±11.6 (1.5–77)
Number with hypertension
(blood pressureX140/90mmHg) (%)
160 (51.1) 3 (25) 102 (71) 51 (37) 4 (27)
Number with anemia (%) 196 (62.6) 4 (33) 102 (71) 76 (54) 14 (94)
Number with hematuria (%) 223 (71.2) 5 (42) 111 (77) 104 (74) 3 (20)
Number with leukocyturia (noninfection) (%) 157 (50.2) 4 (33) 87 (60) 61 (44) 5 (33)
Number with acute renal failure (%) 78 (24.9) 0 (0) 40 (28) 32 (23) 6 (40)
Urine protein (mean±s.d.) (g per 24 h) 4.76±3.28 1.12±0.31 5.68±2.14 4.92±1.19 2.81±0.44
Serum creatinine (mean±s.d.) (mg/dl) 1.32±0.97 0.72±0.11 1.49±0.82 1.38±0.61 1.17±0.24
Duration of follow-up (mean±s.d.) (months) 61.5±34.9 52.3±12.7 65.1±22.1 67.8±31.2 60.6±26.7
Number with doubling of serum creatinine or
end-stage renal disease (%)
37/313 (12) 0 (0) 22 (16) 13 (10) 2 (14)
Numbers in bold were shown as Po0.05 compared with other groups.
Table 3 | Profile of patients with lupus nephritis with repeat renal biopsy
Renal pathology type AI CI I-i T-a I-f
No. Reason for re-biopsy Int Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post
1 Relapse 56 IV-G(A) III(A/C)+V 8 2 2 3 2 1 1 1 1 1
2 Relapse 7 IV-G(A) IV-G(A/C) 11 14 3 4 1 1 1 2 1 2
3 Relapse 23 IV-G(A) IV-G(A/C) 7 17 6 9 2 3 2 3 2 3
4 Relapse 18 III(A) IV-G(A/C) 8 12 4 3 2 1 2 1 2 1
5 Relapse 19 IV-G(A) IV-G(A/C) 9 8 2 4 1 1 1 2 1 2
6 Relapse 46 IV-G(A) IV-G(A/C) 10 8 4 5 2 3 1 3 1 2
7 Relapse 21 III(A) III(A/C) 12 15 3 4 2 2 1 2 1 2
8 Re-evaluation 12 IV-S(A) III(A/C)+V 13 7 1 6 1 2 1 2 0 2
9 Re-evaluation 9 IV-G(A) III(A/C)+V 12 7 2 6 3 2 1 2 1 2
10 Re-evaluation 8 IV-G(A) III(A/C) 14 3 1 3 1 2 1 2 1 2
11 Re-evaluation 11 IV-S(A) III(A/C) 11 4 1 5 1 2 1 2 0 1
Abbreviations: AI, activity index; CI, chronicity index; I-f, interstitial fibrosis; I-i, interstitial inflammatory cell infiltration; Int, interval between biopsies (months); T-a, tubular atrophy.
Kidney International (2010) 77, 820–829 823
F Yu et al.: Tubulointerstitial lesions in lupus nephritis o r ig ina l a r t i c l e
renal prognosis (Po0.001, Po0.001, Po0.001, respectively,
Figure 4a–c). Other univariate risk factors included sex
(male), serum creatinine, renal pathological types, active
indices, cellular crescents, chronic indices, and fibrous
crescents (details in Table 4). Multicenter selection and
immunosuppressants did not affect renal prognosis in the
study. In further multivariate Cox hazard analysis of the three
indices, the three tubulointerstitial indices were confirmed as
independent risk factors for renal outcome by adjustment
using a stepwise model (interstitial infiltration: hazard ratio
1.847, 95% confidence interval: 1.229–2.777, P¼ 0.003;
tubular atrophy: hazard ratio 2.350, 95% confidence interval:
1.019–2.932, P¼ 0.023; interstitial fibrosis: hazard ratio 1.956,
95% confidence interval: 1.237–2.235, P¼ 0.037, respectively;
Table 5a–c). We also found that the value of serum creatinine,
cellular crescents, endocapillary hypercellularity, and fibrous
crescents could independently indicate renal prognosis.
DISCUSSION
SLE is a prototypic autoimmune disease, which comprises a
range of multisystem disorders. Renal involvement is
common in SLE, and the total incidence of renal involvement
among patients with SLE isB40% with variation depending
on geographic area.7,8 There are a number of different types
of renal diseases in SLE, glomerulonephritis being the most
common. In addition to glomerulonephritis, physicians
including nephrologists, pathologists, and rheumatologists
should pay more attention to renal tubulointerstitial lesions
in patients with lupus nephritis, because its presence
might adversely affect the prognosis of renal disease.9–11 In
fact, tubulointerstitial renal disease is found frequently
in patients with lupus nephritis. O’Dell et al.10 found
that tubulointerstitial abnormalities were present in 51% of
the patients with lupus nephritis. Park et al.11 showed that
the prevalence of tubulointerstitial immune deposits was
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Figure 4 |Comparison of renal outcome between patients
with different scores of tubulointerstitial indices in lupus
nephritis. (a) Interstitial inflammatory cell infiltration; (b) tubular
atrophy; (c) interstitial fibrosis.
Table 4 | Univariate survival analysis of patients’ renal
prognosis with lupus nephritis
HR 95% CI P-value
Age 1.028 0.496 2.131 0.941
Sex 0.378 0.177 0.808 0.012
C3 1.339 0.321 5.581 0.689
Proteinuria 1.408 0.695 2.854 0.342
Serum creatinine 24.480 8.647 63.308 o0.001
ANA 0.413 0.213 1.568 0.765
Anti-ds-DNA antibody 1.448 0.708 2.956 0.310
Anti-Sm antibody 0.855 0.390 1.876 0.696
Anti-SSA antibody 0.811 0.412 1.596 0.545
Anti-SSB antibody 3.177 0.436 7.032 0.369
Anti-RNP antibody 0.568 0.259 1.249 0.160
Anti-cardiolipin antibody 0.978 0.431 1.592 0.116
SLEDAI 1.212 0.317 1.698 0.079
Multicenter effect 0.371 0.212 1.541 0.875
Using or not cyclophosphamide 1.675 0.421 1.976 0.087
Renal pathological types 3.278 1.112 3.461 0.037
Activity indices (AIs) score 1.688 1.296 2.198 o0.001
Endocapillary hypercellularity 1.358 0.937 1.969 0.106
Cellular crescents 1.479 1.287 1.7 o0.001
Karyorrhexis/fibrinoid necrosis 1.168 0.900 1.514 0.243
Subendothelial hyaline deposits 0.988 0.736 1.327 0.938
Interstitial inflammatory cell infiltration 3.808 3.748 62.312 o0.001
Glomerular leukocyte infiltration 0.883 0.682 1.144 0.346
Chronicity indices (CIs) score 2.105 1.629 2.720 o0.001
Glomerular sclerosis 1.499 0.977 2.301 0.064
Fibrous crescents 2.634 1.772 3.916 o0.001
Tubular atrophy 3.069 2.115 4.456 o0.001
Interstitial fibrosis 2.583 1.819 3.669 o0.001
Abbreviations: ANA, antinuclear antibody; CI, confidence interval; HR, hazard ratio;
SLEDAI, SLE Disease Activity Index.
Numbers in bold were shown as Po0.05.
824 Kidney International (2010) 77, 820–829
or ig ina l a r t i c l e F Yu et al.: Tubulointerstitial lesions in lupus nephritis
Table 5 | (a) Interstitial inflammatory cell infiltration as the independent risk factor for renal outcome in lupus nephritis;
(b) tubular atrophy as the independent risk factor for renal outcome in lupus nephritis; (c) interstitial fibrosis as the
independent risk factor for renal outcome in lupus nephritis
95% CI
P-value Lower Upper Hazard ratio
(a)
Multivariate Cox hazard analysis
Sex 0.435 0.250 1.815 0.674
Age 0.704 0.494 2.840 1.185
C3 0.311 0.062 2.430 0.387
Serum creatinine o0.001 3.895 40.004 12.483
Proteinuria 0.532 0.351 1.718 0.776
Anti-ds-DNA antibody 0.825 0.456 2.677 1.105
Anti-RNP antibody 0.607 0.254 2.227 0.752
Anti-SSB antibody 0.796 0.808 11.727 4.604
Endocapillary hypercellularity 0.176 0.443 1.161 0.717
Cellular crescents 0.076 0.980 1.497 1.211
Glomerular sclerosis 0.345 0.774 2.082 1.269
Fibrous crescents 0.285 0.776 2.371 1.356
Interstitial inflammatory cell infiltration 0.003 1.267 3.147 1.997
Multivariate stepwise Cox hazard analysis
Serum creatinine o0.001 4.709 44.281 14.440
Cellular crescents 0.011 1.052 1.479 1.247
Endocapillary hypercellularity 0.024 0.440 0.944 0.644
Interstitial inflammatory cell infiltration 0.003 1.229 2.777 1.847
(b)
Multivariate Cox hazard analysis
Sex 0.385 0.249 1.710 0.652
Age 0.820 0.378 2.160 0.904
C3 0.333 0.058 2.634 0.389
Serum creatinine o0.001 3.871 42.554 12.835
Proteinuria 0.987 0.454 2.175 0.993
Anti-ds-DNA antibody 0.327 0.652 3.600 1.533
Anti-RNP antibody 0.496 0.240 1.997 0.692
Anti-SSB antibody 0.381 0.685 12.587 4.998
Endocapillary hypercellularity 0.178 0.440 1.165 0.716
Cellular crescents 0.060 0.991 1.513 1.225
Glomerular sclerosis 0.620 0.676 1.927 1.142
Fibrous crescents 0.235 0.802 2.460 1.404
Tubular atrophy 0.036 1.355 2.532 1.555
Multivariate stepwise Cox hazard analysis
Serum creatinine o0.001 4.554 43.974 14.152
Fibrous crescents 0.003 1.245 2.928 1.909
Tubular atrophy 0.023 1.019 2.932 2.350
(c)
Multivariate Cox hazard analysis
Sex 0.392 0.252 1.716 0.658
Age 0.795 0.375 2.119 0.892
C3 0.422 0.068 3.083 0.458
Serum creatinine o0.001 4.719 48.841 15.181
Proteinuria 0.934 0.469 2.280 1.034
Anti-ds-DNA antibody 0.185 0.861 2.171 1.367
Anti-RNP antibody 0.510 0.245 2.011 0.702
Anti-SSB antibody 0.772 0.077 12.917 5.179
Endocapillary hypercellularity 0.119 0.422 1.104 0.682
Cellular crescents 0.059 0.992 1.512 1.225
Glomerular sclerosis 0.619 0.668 1.971 1.147
Fibrous crescents 0.312 0.760 2.357 1.339
Interstitial fibrosis 0.018 1.631 3.568 2.501
Multivariate stepwise Cox hazard analysis
Serum creatinine o0.001 7.772 66.116 22.669
Cellular crescents 0.002 1.099 1.532 1.298
Endocapillary hypercellularity 0.040 0.445 0.981 0.661
Interstitial fibrosis 0.037 1.237 2.235 1.956
Abbreviation: CI, confidence interval.
Numbers in bold were shown as Po0.05.
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33% by immunofluorescence and 23% by electron micro-
scopy in a cohort of 93 patients with lupus nephritis.
Therefore, a comprehensive classification of lupus nephritis,
which should also cover tubulointerstitial parameters, is very
important for physicians to guide treatment and predict
prognosis in patients with lupus nephritis.
The 2003 ISN/RPS classification of lupus nephritis
has been widely used all over the world,6,12–14 although
the significance and rationality of the classification need to
be examined in many centers in different parts of the
world.12,13 Is it rational for the new classification based on
glomerular lesions to represent the full characteristics of
lupus nephritis, and do tubulointerstitial lesions also have an
important role in the progression of lupus nephritis? To
provide answers for these questions, a systemic pathological
analysis of tubulointerstitial lesions in a large cohort of Chinese
patients with lupus nephritis, from five renal centers in North
China, with different classes based on the new classification
was carried out.
Importantly, we should indicate that the NIH (National
Institutes of Health) scoring system, used to evaluate tubulo-
interstitial lesions, has gained widespread acceptance.9,15–17
A more detailed and complex biopsy index proposed by
Hill et al.18 has an even stronger predictive value, but is too
laborious for routine use and remains a valuable research tool.19
Our study showed that there exist different severity of
tubulointerstitial lesions in different classes of lupus
nephritis, which are graded as class IV4class III4class II
and class V, and it seems that tubulointerstitial lesions are
consistent with glomerular injury under the new classifica-
tion. Further correlation test in the current study also
illustrated that tubulointerstitial lesions correlated with some
glomerular indices in lupus nephritis. Glomerular features of
activity, including cellular crescents, karyorrhexis/fibrinoid
necrosis, and subendothelial hyaline deposits, were highly
consistent with the degree of interstitial inflammatory cell
infiltration (r40.4). Similarly, the glomerular features of
chronicity, such as glomerular sclerosis and fibrotic crescents,
were consistent with the range of tubular atrophy and
interstitial fibrosis as well. However, the r-value was not
always strong enough (in some indices, ro0.4), and we really
found that some cases presented with severe glomerular
injury but with mild tubulointerstitial change and vice versa.
For patients with more severe glomerular involvement but
milder tubulointerstitial injury, they might be at the early
stage of lupus nephritis because they were in the shortest
interval between presentation of lupus nephritis and biopsy
in this study. This implies that interstitial lesions might be the
consequence of glomerular injury in these patients. However,
for those patients with milder glomerular injury and more
prominent tubulointerstitial change, as well as for those with
nonparallel changes in repeat renal biopsy (glomerular
indices meliorated but tubulointerstitial scores deteriorated
in the four patients with clinical remission), we proposed that
tubulointerstitial lesions may be not only a consequence of
glomerular injury but also an important player in lupus
nephritis. For some patients, the interstitial changes may be
the major renal lesions as reported previously.20–25 Interest-
ingly, our further multivariate Cox hazard analysis showed
that the risk of doubling creatinine or end-stage renal disease
increases in proportion to increasing tubulointerstitial
lesions, and that the degree of tubulointerstitial lesions,
including interstitial inflammatory cell infiltration, intersti-
tial fibrosis, and tubular atrophy could have independent
prognostic value in predicting renal outcome, although some
classical risk factors, including sex (male), serum creatinine,
renal pathological types, active indices, cellular crescents,
chronic indices, and fibrous crescents, were also confirmed as
predictors of renal prognosis in our study. The reasons why
patients with more severe tubulointerstitial lesions were
associated with a worse renal prognosis might be attributed
to irreversible chronic and sclerotic lesions, which are
refractory to therapy. As for ‘active’ interstitial inflammatory
cell infiltration, some studies showed that proteinuria is a risk
factor for the deterioration of renal function, which is in part
a result of interstitial inflammation.17 In fact, Yamamoto
et al.26 already compared interstitial inflammatory and
chronic tubulointerstitial lesions between patients with lupus
nephritis and those with IgA nephropathy. They found that
no IgA nephropathy patient with nil or mild glomerular
lesions had moderate or severe interstitial inflammatory and/
or chronic tubulointerstitial lesions, but predominantly
severe interstitial inflammatory lesions were found in 36%
of lupus nephritis patients with nil or mild glomerular
lesions. Many previous studies also reported cases with
significant tubulointerstitial involvement in lupus nephri-
tis.20–25 Some investigators proposed different pathogenic
mechanisms inducing tubulointerstitial injury in experi-
mental and human lupus nephritis. These factors
include immune complex deposition,23,26,27 albuminuria
macrophage chemokines,28–33 some autoantibodies,34,35 and
others.36 Recent studies suggested that activation of tubular
Toll-like receptor-9 had a pathogenic role in tubulointerstitial
inflammation and damage in lupus nephritis.37–39 In some
patients who underwent repeat renal biopsy, it was shown
that tubulointerstitial scores deteriorated, although the
patients achieved clinical remission after immunosuppressive
treatment. Therefore, further therapies aimed directly at
tubulointerstitial injury based on above studies should be
investigated in lupus nephritis.
The most controversial aspect of the ISN/RPS 2003 classi-
fication is the introduction of subclass segmental ‘IV-S’
and global ‘IV-G’ within diffuse lupus nephritis (class IV).
This stratification raises two fundamental questions: (1) Are
there differences in therapeutic response and prognosis
between these two subclasses? (2) Is there any pathogenic
difference between the two subclasses or just a continuum of
one disease? Many studies have examined the distinction
between the two groups.17,40–43 Collectively, these studies
suggest that lupus nephritis class IV-S and IV-G probably
represent different stages or morphological expressions
within a single disease continuum,13,44 although there might
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exist pathogenic differences between the two groups.42,45 The
recent study from our center showed that the frequency of
serum anti-neutrophil cytoplasmic antibodies was signifi-
cantly higher in IV-S than in IV-G (20 vs 4.6%, P¼ 0.008),
whereas frequencies of anti-C1q IgG1 and IgG3 subclasses
were significantly higher in IV-G (P¼ 0.006, P¼ 0.011,
respectively). These data indicate that ‘immune complex’ or
‘pauci-immune’ might be prominent in the pathogenesis of
subclass IV-G or IV-S, respectively.46 In the current study, we
found that the score of interstitial inflammatory cell
infiltration in patients with subclass IV-G was significantly
higher than in those with subclass IV-S, but the scores of
tubulointerstitial indices in class IV-S and class III were
similar. On the basis of our own findings, we speculated that
class III and subclass IV-S might be mild or early stage to
subclass IV-G. However, this observation requires more
studies for clarification, including the analysis of treatment
response and long-term prognosis of patients with class III,
IV-S, and IV-G in the future.
Another important change in the new classification is that
in classes III and IV, the proportion of glomeruli affected by
active (A) and chronic (C) lesions should be indicated. We
found that there was a tendency of more tubular atrophy and
interstitial fibrosis in patients with both active and chronic
lesions than in those with pure active lesions in class III and
class IV. This finding might provide an additional explana-
tion for the recent observation made by Hiramatsu et al.17
that renal function declined only in patients with IV-G (A/C)
in spite of intensified therapies.
There were some limitations in this study. First, it is not a
prospective study with well-controlled treatment schedules;
there was some heterogeneity in the treatment that may have
influenced the associations between histological features and
outcome, although most patients were treated with cyclo-
phosphamide. Second, the sample size of patients with
nonparalleled glomerular and tubulointerstitial lesions is still
not large enough to draw the valid conclusion. Third, the
current study lacks investigation on pathogenic mechanism
on tubulointerstitial injury in lupus nephritis. Therefore, a
further well-designed prospective study is required.
In conclusion, the 2003 ISN/RPS classification of lupus
nephritis based on glomerular lesions could also reflect the
related tubulointerstitial lesions, and the revised classification
with a description of the degree of tubulointerstitial lesions
might be helpful in predicting renal outcome in lupus
nephritis.
MATERIALS AND METHODS
Patients
Renal histopathological data of 313 patients with renal biopsy-
proven lupus nephritis, diagnosed between January 2003 and June
2007 from five hospitals in North China, were reviewed and
reclassified according to the ISN/RPS 2003 classification by four
experienced pathologists. Of the 313 patients, 208 were from the
Peking University First Hospital, 37 from the Affiliated Hospital of
Ningxia Medical University, 34 from the Cangzhou Central
Hospital, 20 from the First Affiliated Hospital Baotou Medical
College, and 14 were from the Chifeng Second Hospital. The
pathologists classified and scored the biopsies separately, blinded to
patients’ data and scores of other observers. Patients with o10
glomeruli in their renal biopsies and patients with other known
superimposed tubulointerstitial diseases were excluded. In this
study, cases of IIIþV were classified as class III and cases of IVþV
were classified as class IV. Patients who fulfilled the 1997 American
College of Rheumatology revised criteria for SLE were included.47
The disease activity was assessed by the SLEDAI (SLE Disease
Activity Index).48,49
Renal histopathology
Renal biopsy specimens were examined by light microscopy, direct
immunofluorescence, and electron microscopy techniques.
Light microscopy examination. Renal biopsy specimens were
fixed in 4.5% buffered formaldehyde for light microscopy.
Consecutive serial 2-mm thick sections were used for histological
staining. Stains used included hematoxylin and eosin, periodic acid-
Schiff, silver methenamine, and Masson’s trichrome. Pathological
parameter such as activity indices and chronicity indices were
approached by renal pathologists using a modified previously
reported system involving semi-quantitative scoring of specific
biopsy features.9,15 According to the revised Austin’s semi-
quantitative scoring system,26 glomerular lesions were graded as
following: 0 (nil), almost normal glomeruli by light microscopy; 1þ
(mild), glomeruli having focal segmental mesangial proliferation
free of segmental sclerosis and adhesion of tufts to Bowman’s
capsules; 2þ (moderate), proliferative changes extended moder-
ately to peripheral capillary walls; 3þ (severe), severe and diffuse
proliferative changes and/or segmental or global sclerosis. The
scoring of interstitial inflammatory cell infiltration was as following:
0 (nil), normal; 1þ (mild), o25% of the acreage of interstitium
affected; 2þ (moderate), 25–50% of the acreage of interstitium
affected; 3þ (severe), 450% of the acreage of interstitium affected
in each specimen. The scoring of interstitial fibrosis and tubular
atrophy was assessed similarly. Differences in scoring between the
pathologists were resolved by re-reviewing the biopsies and thus
reaching a consensus.
Direct immunofluorescence examination. Results of direct
immunofluorescence for IgG, IgA, IgM, C3, C1q, and fibrin deposits
were semi-quantitatively graded from 0 to 4 according to the
intensity of fluorescence.
Electron microscopy examination. Renal biopsy specimens
were fixed in 2.5% paraformaldehyde for electron microscopy. After
being embedded in epon, ultra-thin sections were mounted on
metal grids and stained with uranyl acetate before being viewed
under a transmission electron microscope (JEM-1230; JEOL, Tokyo,
Japan).
Clinical evaluation
The detailed clinical data of patients were retrospectively analyzed.
Serum antinuclear antibodies were detected using indirect immuno-
fluorescence assay (EUROIMMUN, Lu¨beck, Germany) and anti-
double-stranded DNA antibodies were detected using Crithidia
luciliae indirect immunofluorescence test (EUROIMMUN).
Anti-extractable nuclear antigen antibodies, including anti-Sm,
anti-Sjo¨gren’s syndrome A antigen, anti-Sjo¨gren’s syndrome B
antigen, and anti-ribonucleo protein antibodies, were detected
using immunodotting assay (EUROIMMUN). Anti-cardiolipin
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antibodies were detected using ELISA (enzyme-linked immunosor-
bent assay) (EUROIMMUN). Serum C3 was determined using rate
nephelometry assay (Beckman-Coulter, IMMAGE, Fullerton, CA,
USA, normal range40.85 g/l).
Response to therapy includes complete remission, partial remis-
sion, and treatment failure detailed in previous studies.50–53
Patients were followed up in outpatient lupus clinics. The primary
end point was defined as death, and the secondary end point was
defined as end-stage renal disease or doubling of serum creatinine.
Informed consent was obtained for renal biopsy from each
patient. The research was in compliance with the Declaration of
Helsinki.
Statistical analysis
Statistical software SPSS 13.0 (SPSS, Chicago, IL, USA) was used for
statistical analysis. Quantitative data were expressed as mean±s.d.,
and median with range (minimum, maximum). Differences of semi-
quantitative data were tested with the Kruskal–Wallis test and the
Mann–Whitney U-test. The Spearman rank-order correlation test
was performed between various lesions (r-value: 0.2–0.4 as mild
correlation; 0.4–0.8 as moderate correlation; 40.8 as high correla-
tion). Kaplan–Meier curves were used to analyze patients’ prognosis.
Univariate survival analysis was carried out using the log-rank test.
Multivariate analysis of patient survival was performed using the
Cox regression model. The following variables were assessed as
potential predictors of renal outcomes: age, sex, proteinuria, serum
creatinine, complement 3, antinuclear antibodies, anti-ds-DNA
antibodies, anti-extractable nuclear antigen antibodies, anti-cardi-
olipin antibodies, SLEDAI, renal pathological types, activity indices,
including endocapillary hypercellularity, cellular crescents, karyor-
rhexis/fibrinoid necrosis, subendothelial hyaline deposits, interstitial
inflammation and leukocyte glomerular infiltration, chronicity indices,
including glomerular sclerosis, fibrous crescents, tubular atrophy,
and interstitial fibrosis, the influence of using cyclophosphamide and
multi-centers effect. Variables that did not affect survival significantly
were removed by a stepwise procedure according to a likelihood ratio.
Results were expressed as hazard ratio with 95% confidence intervals.
Statistical significance was considered as Po0.05.
DISCLOSURE
All the authors declared no competing interests.
ACKNOWLEDGMENTS
This study was supported by the Program for Changjiang Scholars
and Innovative Research Team in University (PCSIRT-IRT0803).
REFERENCES
1. Appel GB, Radhakrishnan J, D’Agati V. Secondary glomerular disease. In:
Brenner BM (ed). Brenner & Rector’s The Kidney, 8th edn. Philadephia: W.B.
Saunders, 2008, pp 1067–1146.
2. D’Agati V. Renal disease in systemic lupus erythematosus, mixed
connective tissue disease, Sjogren’s syndrome, and rheumatoid
arthritis. In: Jennette JC, Olson JL, Schwartz MM et al. (eds). Heptinstall’s
Pathology of the Kidney, 6th edn. Lippincott-Raven: Philadephia, 2007,
pp 517–612.
3. McCluskey R. Lupus Nephritis. Appleton-Centery-Crofts: East Norwalk,
CT, 1975.
4. Churg J, Sobin L. Renal Disease: Classification and Atlas of Glomerular
Disease. Igaku-Shoin: Tokyo, 1982.
5. Churg J, Bernstein J, Classock RJ. Renal Disease: Classification and Atlas of
Glomerular Disease. Igaku-Shoin: Tokyo, 1995.
6. Weening JJ, D’Agati VD, Schwartz MM et al. The classification of
glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int
2004; 65: 521–530.
7. Cervera R, Abarca-Costalago M, Abramovicz D et al. Systemic lupus
erythematosus in Europe at the change of the millennium: lessons from
the ‘Euro-Lupus Project’. Autoimmun Rev 2006; 5: 180–186.
8. Cervera R, Font J, Shoenfeld Y, European Working Party on Systemic
Lupus Erythematosus. European Working Party on Systemic Lupus
Erythematosus: A 15-year Report. Autoimmun Rev 2006; 5: 549–553.
9. Austin III HA, Muenz LR, Joyce KM et al. Diffuse proliferative lupus
nephritis: identification of specific pathologic features affecting renal
outcome. Kidney Int 1984; 25: 689–695.
10. O’Dell JR, Hays RC, Guggenheim SJ et al. Tubulointerstitial renal disease in
systemic lupus erythematosus. Arch Intern Med 1985; 145: 1996–1999.
11. Park MH, D’Agati V, Appel GB et al. Tubulointerstitial disease in lupus
nephritis: relationship to immune deposits, interstitial inflammation,
glomerular changes, renal function, and prognosis. Nephron 1986; 44:
309–319.
12. Markowitz GS, D’Agati VD. The ISN/RPS 2003 classification of lupus
nephritis: an assessment at 3 years. Kidney Int 2007; 71: 491–495.
13. Markowitz GS, D’Agati VD. Classification of lupus nephritis. Curr Opin
Nephrol Hypertens 2009; 18: 220–225.
14. Seshan SV, Jennette JC. Renal disease in systemic lupus erythematosus
with emphasis on classification of lupus glomerulonephritis: advances
and implications. Arch Pathol Lab Med 2009; 133: 233–248.
15. Austin III HA, Boumaps DT, Vaughan EM et al. Predicting renal outcomes
in severe lupus nephritis: contributions of clinical and histologic data.
Kidney Int 1994; 45: 544–550.
16. Korbet SM, Lewis EJ, Schwartz MM et al. Factors predictive of outcome
in severe lupus nephritis. Am J Kidey Dis 2000; 35: 904–914.
17. Hiramatsu N, Kuroiwa T, Ikeuchi H et al. Revised classification of lupus
nephritis is value in predicting outcome with an indication of the
proportion of glomeruli affected by chronic lesions. Rheumatology
(Oxford) 2008; 47: 702–707.
18. Hill GS, Delahousse M, Nochy D et al. A new morphologic index for the
evaluation of renal biopsies in lupus nephritis. Kidney Int 2000; 58:
1160–1173.
19. Zappitelli M, Duffy CM, Bernard C et al. Evaluation of activity, chronicity
and tubulointerstitial indices for childhood lupus nephritis. Pediatr
Nephrol 2008; 23: 83–91.
20. Singh AK, Ucci A, Madias NE. Predominant tubulointerstitial lupus
nephritis. Am J Kidney Dis 1996; 27: 273–278.
21. Fang JT, Chen YC. Systemic lupus erythematosus presenting initially as
hydrogen ATPase pump defects of distal renal tubular acidosis. Ren Fail
2000; 22: 647–652.
22. Mori Y, Kishimoto N, Yamahara H et al. Predominant tubulointerstitial
nephritis in a patient with systemic lupus nephritis. Clin Exp Nephrol 2005;
9: 79–84.
23. Hayakawa S, Nakabayashi K, Karube M et al. Tubulointerstitial immune
complex nephritis in a patient with systemic lupus erythematosus: role of
peritubular capillaritis with immune complex deposits in the pathogenesis
of the tubulointerstitial nephritis. Clin Exp Nephrol 2006; 10: 146–151.
24. Omokawa A, Wakui H, Okuyama S et al. Predominant tubulointerstitial
nephritis in a patient with systemic lupus erythematosus: phenotype of
infiltrating cells. Clin Nephrol 2008; 69: 436–444.
25. Hodgin JB, Whelan J, Markowitz GS et al. Giant cell tubulitis with immune
complex deposits in a patient with lupus nephritis. Am J Kidney Dis 2009;
53: 513–517.
26. Yamamoto T, Nagase M, Hishida A et al. Interstitial inflammatory and
chronic tubulointerstitial lesions in lupus nephritis: comparison with
those in IgA nephropathy. Lupus 1993; 2: 261–268.
27. Schwartz MM, Fennell JS, Lewis EJ. Pathologic changes in the renal tubule
in systemic lupus erythematosus. Hum Pathol 1982; 13: 534–547.
28. Alexopoulos E, Seron D, Hartley RB et al. Lupus nephritis: correlation of
interstitial cells with glomerular function. Kidney Int 1990; 37: 100–109.
29. Hurtado A, Asato C, Escudero E et al. Clinicopathologic correlations in
lupus nephritis in Lima, Peru. Nephron 1999; 83: 323–330.
30. Hill GS, Delahousse M, Nochy D et al. Proteinuria and tubulointerstitial
lesions in lupus nephritis. Kidney Int 2001; 60: 1893–1903.
31. Zheng L, Sinniah R, Hsu SI. Renal cell apoptosis and proliferation may be
linked to nuclear factor-kappaB activation and expression of inducible
nitric oxide synthase in patients with lupus nephritis. Hum Pathol 2006;
37: 637–647.
32. Zheng L, Sinniah R, Hsu SI. Pathogenic role of NF-kappaB activation in
tubulointerstitial inflammatory lesions in human lupus nephritis.
J Histochem Cytochem 2008; 56: 517–529.
33. Ferraccioli G, Romano G. Renal interstitial cells, proteinuria and
progression of lupus nephritis: new frontiers for old factors. Lupus 2008;
17: 533–540.
828 Kidney International (2010) 77, 820–829
or ig ina l a r t i c l e F Yu et al.: Tubulointerstitial lesions in lupus nephritis
34. Yung S, Tsang RC, Sun Y et al. Effect of human anti-DNA antibodies on
proximal renal tubular epithelial cell cytokine expression: implications
on tubulointerstitial inflammation in lupus nephritis. J Am Soc Nephrol
2005; 16: 3281–3294.
35. Tan Y, Yu F, Yang H et al. Autoantibodies against monomeric C-reactive
protein in sera from patients with lupus nephritis are associated with
disease activity and renal tubulointerstitial lesions. Hum Immunol 2008;
69: 840–844.
36. Moll S, Menoud PA, French L et al. Tubular up-regulation of clusterin
mRNA in murine lupus-like nephritis. Am J Pathol 1998; 152: 953–962.
37. Anders HJ, Banas B, Schlo¨ndorff D. Signaling danger: toll-like receptors
and their potential roles in kidney disease. J Am Soc Nephrol 2004; 15:
854–867.
38. Anders HJ, Vielhauer V, Eis V et al. Activation of toll-like receptor-9
induces progression of renal disease in MRL-Fas(lpr) mice. FASEB J 2004;
18: 534–536.
39. Benigni A, Caroli C, Longaretti L et al. Involvement of renal tubular
Toll-like receptor 9 in the development of tubulointerstitial injury in
systemic lupus. Arthritis Rheum 2007; 56: 1569–1578.
40. Mittal B, Hurwitz S, Rennke H et al. New subcategories of class IV lupus
nephritis: are there clinical, histologic, and outcome differences?
Am J Kidney Dis 2004; 44: 1050–1059.
41. Yokoyama H, Wada T, Hara A et al. the Kanazawa Study Group for Renal
Diseases and Hypertension. The outcome and a new ISN/RPS 2003
classification of lupus nephritis in Japanese. Kidney Int 2004; 66:
2382–2388.
42. Hill GS, Delahousse M, Nochy D et al. Class IV-S versus class IV-G lupus
nephritis: clinical and morphologic differences suggesting different
pathogenesis. Kidney Int 2005; 68: 2288–2297.
43. Kim YG, Kim HW, Cho YM et al. The difference between lupus nephritis
class IV-G and IV-S in Koreans: focus on the response to cyclophos-
phamide induction treatment. Rheumatology (Oxford) 2008; 47: 311–314.
44. Schwartz MM, Korbet SM, Lewis EJ. The prognosis and pathogenesis
of severe lupus nephritis. Nephrol Dial Transplant 2008; 23:
1298–1306.
45. Najafi CC, Korbet SM, Lewis EJ et al. Significance of histologic patterns of
glomerular injury upon long-term prognosis in severe lupus
glomerulonephritis. Kidney Int 2001; 59: 2156–2163.
46. Yu F, Tan Y, Wu LH et al. Class IV-G and IV-S lupus nephritis in Chinese
patients: a large cohort study from a single center. Lupus 2009; 18:
1073–1081.
47. Hochberg MC. Updating the American College of Rheumatology revised
criteria for the classification of systemic lupus erythematosus. Arthritis
Rheum 1997; 40: 1725.
48. Bombardier C, Gladman DD, Hocherg M. Validity and reliability of six
systems for the clinical assessment of disease activity in systemic lupus
erythematosus. Arthritis Rheum 1989; 32: 1107–1118.
49. Bombardier C, Gladman DD, Urowitz MB et al. The derivation of the
SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992;
35: 630–640.
50. Wang J, Hu W, Xie H et al. Induction therapies for class IV lupus
nephritis with non-inflammatory necrotizing vasculopathy:
mycophenolate mofetil or intravenous cyclophosphamide.
Lupus 2007; 16: 707–712.
51. Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or
intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;
353: 2219–2228.
52. Chan TM, Tse KC, Tang CS et al. Long-term outcome of patients with
diffuse proliferative lupus nephritis treated with prednisolone and
oral cyclophosphamide followed by azathioprine. Lupus 2005; 14:
265–272.
53. Wang HY, Cui TG, Hou FF et al. Induction treatment of proliferative lupus
nephritis with leflunomide combined with prednisone: a prospective
multi-center observational study. Lupus 2008; 17: 638–644.
Kidney International (2010) 77, 820–829 829
F Yu et al.: Tubulointerstitial lesions in lupus nephritis o r ig ina l a r t i c l e
